BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
This week we will present at the thematic school “From 3D culture to the organoid: multidisciplinary research” organised by the Institute of Biological Sciences of CNRS (France) in Strasbourg. Study director Méryl Roudaut will talk Read more…
It is our pleasure to announce that the article of our PhD Student Véronique De Conto has been published in Toxicology in vitro journal. This work comes from a collaboration between HCS Pharma and Inserm Read more…
Want to try 3D cell culture in your lab? Why not testing BIOMIMESYS®, our 3D cell culture system made in France? Please feel free to contact us at hello@biomimesys.com (or with this form) for any Read more…
We are very please to participate to the online Investment Forum of EUTECH, beginning august 24th. You will find us on booth 103 and we will be available for online meeting. As we are in Read more…
In the brain, we have about 100 billion of neurons but they represent only 10 to 50% of the total cells (von Bartheld et al., 2016). Indeed, glial cells, including astrocytes, oligodendrocytes and microglia are Read more…
Summer is alway a good time to improve our services. Then we are very happy to introduce our updated Skin Pigmentation and Oxidative Stress services. Pigmentation is particularly regulated at the cellular level by melanocytes synthesizing melanin within Read more…
We are pleased to announce that HCS Pharma secured 20 Million EUR capital commitment from GEM group following the public listing of the company shares on a European stock exchange. We are under the IPO Read more…
We are very please to welcome Dr Isabelle Van Seuningen (Director of CANTHER laboratories & Director of ONCOLille Cancer Institute) and Dr Vincent Senez (Research Director CNRS/CANTHER Laboratory/ONCOLille Institute) in our serie of talk about Read more…
We were glad to welcome Roberta Bilardo for a 2 month-secondment in HCS Pharma in the frame of Nanostem project (Developing NANOmaterials for neural STEM cells drug delivery). She is working as a Marie Curie Read more…
Today is the opening of the virtual part of 2021 BIO-Asia Taiwan and we are happy to welcome you on our booth (R332) to present our latest innovations with BIOMIMESYS® for liver organoids. This event Read more…
Our project leader Dr Meryl Roudaut was invited to present at the last ISVHLD congress, the Global Hepatitis Summit, in Taiwan. The theme of the summit, “Evolution and Revolution of Viral Hepatitis and Liver Disease”, Read more…
As part of their engineering studies at ISEN Lille for a master’s degree specialized in Bionanotechnologies, Robin and Orégane arrived in HCS Pharma in May 2021 for a 4-month internship. Their work in HCS Pharma Read more…
We are really pleased to announce that we have officially created a representative office in Taïwan (company 仿生培養技術中心 ID number 90729614) which is directed by our partner, Joseph Chou 周肇隆 ジョーゼフ・チョウ, member of our advisory board. Read more…
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using Read more…
Since the beginning of this year we have created four webinars to present our BIOMIMESYS® technology and practical uses. We have chosen to focus on the scientific side of our innovation by presenting results in Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.